1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1128/AAC.03643-14" target="_blank" rel="noreferrer noopener">http://doi.org/10.1128/AAC.03643-14</a>
Pages
1119–1126
Issue
2
Volume
59
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.
Publisher
An entity responsible for making the resource available
Antimicrobial agents and chemotherapy
Date
A point or period of time associated with an event in the lifecycle of the resource
2015
2015-02
Subject
The topic of the resource
Adult; Aged; Anti-Bacterial Agents/*therapeutic use; Bacterial/*drug therapy; Ceftriaxone/*therapeutic use; Cephalosporins/*therapeutic use; Community-Acquired Infections/*drug therapy; Female; Humans; Male; Middle Aged; Pneumonia; Treatment Outcome
Creator
An entity primarily responsible for making the resource
Lodise Thomas P; Anzueto Antonio R; Weber David J; Shorr Andrew F; Yang Min; Smith Alexander; Zhao Qi; Huang Xingyue; File Thomas M
Description
An account of the resource
The primary driver of health care costs for patients with community-acquired pneumonia (CAP) is the hospital length of stay (LOS). Unfortunately, hospital LOS comparisons are difficult to make from phase III CAP trials because of their structured designs and prespecified treatment durations. However, an opportunity still exists to draw inferences about potential LOS differences between treatments through the use of surrogates for hospital discharge. The intent of this study was to quantify the time to a clinical response, a proxy for the time to discharge readiness, among hospitalized CAP patients who received either ceftaroline or ceftriaxone in two phase III CAP FOCUS clinical trials. On the basis of the Infectious Diseases Society of America and American Thoracic Society CAP management guidelines and recent FDA guidance documents for community-acquired bacterial pneumonia, a post hoc adjudication algorithm was constructed a priori to compare the time to a clinical response, a proxy for the time to discharge readiness, between patients who received ceftaroline or ceftriaxone. Overall, 1,116 patients (ceftaroline, n=562; ceftriaxone, n=554) from the pooled FOCUS trials met the selection criteria for this analysis. Kaplan-Meier analyses showed that ceftaroline was associated with a shorter time, measured in days, to meeting the clinical response criteria (P=0.03). Of the patients on ceftaroline, 61.0, 76.1, and 83.6% achieved a clinical response by days 3, 4, and 5, compared to 54.3, 69.8, and 79.3% of the ceftriaxone-treated patients. In the Cox regression, ceftaroline was associated with a shorter time to a clinical response (HR, 1.16, P=0.02). The methodology employed here provides a framework to draw comparative effectiveness inferences from phase III CAP efficacy trials. (The FOCUS trials whose data were analyzed in this study have been registered at ClinicalTrials.gov under registration no. NCT00621504 and NCT00509106.).
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1128/AAC.03643-14" target="_blank" rel="noreferrer noopener">10.1128/AAC.03643-14</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2015
Adult
Aged
Anti-Bacterial Agents/*therapeutic use
Antimicrobial agents and chemotherapy
Anzueto Antonio R
Bacterial/*drug therapy
Ceftriaxone/*therapeutic use
Cephalosporins/*therapeutic use
Community-Acquired Infections/*drug therapy
Department of Internal Medicine
Female
File Thomas M
Huang Xingyue
Humans
Lodise Thomas P
Male
Middle Aged
NEOMED College of Medicine
Pneumonia
Shorr Andrew F
Smith Alexander
Treatment Outcome
Weber David J
Yang Min
Zhao Qi